Antitumor effect of isoquercetin on tissue vasohibin expression and colon cancer vasculature
Metrics: PDF 594 views | Full Text 1365 views | ?
Daniel de Castilho da Silva1,*, Guilherme Di Camillo Orfali2,*, Maycon Giovani Santana3, Jessica Kaoru Yamamoto Palma3, Isabella Ramos de Oliveira Assunção3, Isadora Moraes Marchesi2, Ana Yoshie Kitagawa Grizotto2, Natália Peres Martinez1, Simone Felliti4, José Aires Pereira5 and Denise Gonçalves Priolli6
1 Programme Stricto Sensu in Health Science, Sao Francisco University Medical School, Sao Paulo, Brazil
2 Escola Paulista de Medicina, São Paulo, Brazil
3 Scientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo, Brazil
4 Department of Oncology, Sao Francisco University Medical School, Sao Paulo, Brazil
5 Department of Pathology, Sao Francisco University Medical School, Sao Paulo, Brazil
6 Postgraduate Programme Stricto Sensu in Health Science, Sao Francisco University Medical School, Sao Paulo, Brazil
* These authors contributed equally to this work
|Denise Gonçalves Priolli,||email:||firstname.lastname@example.org|
Keywords: target; angiogenic proteins; neoplasms; flavonols; antitumor assays-xenograft model
Received: September 24, 2021 Accepted: December 08, 2021 Published: February 08, 2022
Tumor cells trigger angiogenesis through the expression of angiogenic factors. Vasohibins (VASHs) are a family of peptides that regulate angiogenesis. Flavonoids have antiproliferative antitumor properties; however, few studies have highlighted their antiangiogenic potential. This study evaluated the flavonoid isoquercetin (Q3G) as an antitumor compound related to colon cancer vascularization and regulation of VASH1 and 2. Mice bearing xenogeneic colon cancer (n = 15) were divided into 3 groups: Q3G-treated (gavage, daily over a week), bevacizumab-treated (intraperitoneal, single dose), or untreated animals. Tumor growth, histological characteristics, blood vessel volume, and VASH1 and 2 expressions were analyzed. Q3G impaired tumor growth and vascularization, upregulated VASH1, and downregulated VASH2 in comparison to untreated animals. Mice treated with Q3G showed approximately 65% fewer blood vessels than untreated animals and 50% fewer blood vessels than mice treated with bevacizumab. Thus, we show that Q3G has antitumor activity, impairs vascularization, and differentially modulates VASH1 and 2 expressions in colon cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.